Dementia

#Clinical trial design #Dementia #Funding #Neurodegenerative disorders #University College London

UK dementia research gets £49.9 million funding boost

Head of clinical trials at the University College London (UCL) Dementia Research Centre, Dr Cath Mummery, has been announced as the Director of a new network of dementia trial sites across the country. The UK government has authorised £49.9 ($63.4) million of new funding to improve… Read More

#Editor's Choice #News

Human brain
#Age-related diseases (ARDs) #Dementia #Gene mutation #Neurodegenerative disorders #Organoids

Organoid research sheds light on gene mutation linked to dementia

New understanding of a gene that is linked to some forms of dementia and other age-related diseases gives scientists fresh hope that action can be taken against these diseases long before the onset of symptoms. The gene – called Angiogenin or ANG – is associated with… Read More

#Editor's Choice #News

#Cancer research #Dementia #Motor neurone disease #Neuroscience #Osteoarthritis #Schizophrenia

New DDW Highlights episode out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news highlights this week are mostly focused around neuroscience, with new guiding principles… Read More

#News

#Cancer research #Dementia #Motor neurone disease #Neuroscience #Osteoarthritis #Schizophrenia

This week in drug discovery (4-8 December) 

News round-up for 4-8 December by DDW Digital Content Editor Diana Spencer. The news highlights this week are mostly focused around neuroscience, with new guiding principles and a drug repurposing fund launched for motor neuron disease research, a new drug target found for early-onset dementia, and a… Read More

#News

Jigsaw puzzle of the brain
#Cryo-EM #Dementia #Medical Research Council #Motor neurone disease #Neurodegenerative disorders #Neuroscience

Researchers identify potential drug target for early-onset dementia

Scientists have identified abnormal aggregates of a protein called TAF15 in the brains of individuals with early-onset dementia, known as frontotemporal dementia, where the cause was not previously known. The research led by scientists from the Medical Research Council (MRC) Laboratory of Molecular Biology, in Cambridge,… Read More

#Editor's Choice #News

Stephen Back and Philip Adeniyi, OHSU School of Medicine
#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroscience #Oregon Health & Science University

Scientists discover new target for Alzheimer’s drugs

Researchers have discovered a new avenue of cell death in Alzheimer’s disease and vascular dementia. A new study, led by scientists at Oregon Health & Science University (OHSU), has revealed that a form of cell death known as ferroptosis – caused by a build-up of iron… Read More

#Editor's Choice #News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week reflects the high level of interest and investment in… Read More

#News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

This week in drug discovery (21-25 August)  

News round-up for 21-25 August by DDW Digital Content Editor Diana Spencer. The headline news this week reflects the high level of interest and investment in neuroscience drug discovery, particularly neurodegenerative diseases like Alzheimer’s; including positive clinical trial results for new immunotherapy and biotherapeutic candidates, and… Read More

#News

Ozempic Insulin injection pen
#Alzheimer's #Dementia #Nicotine addiction #Novo Nordisk #Type 2 diabetes

Could GLP-1 receptor agonists like Ozempic treat addiction and dementia?

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. Semaglutide manufacturer Novo Nordisk reported earlier this month that the drug reduces the risk… Read More

#News #Trending News

Dementia
#Alzheimer's #Dementia #Inherited tauopathies #Neurodegenerative disorders #Neuroscience #Oligomerix

Preclinical data supports new approach to Alzheimer’s disease

Preclinical data has demonstrated that the oral small molecule OLX-07010 inhibits tau aggregation in a model for inherited tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Earlier this year, the company Oligomerix announced the first-in-human dosing of OLX-07010 in a Phase Ia clinical… Read More

#Editor's Choice #News

Dementia
#Alzheimer's #Dementia #FDA #Lundbeck #Otsuka #Phase III trial

FDA approves first drug for agitation due Alzheimer’s dementia

Otsuka and Lundbeck’s Rexulti (brexpiprazole) has become the first pharmacological treatment to be approved in the US for agitation associated with dementia due to Alzheimer’s disease. The Food and Drug Administration (FDA) has approved the companies’ supplemental New Drug Application (sNDA). Agitation is a common neuropsychiatric symptom in Alzheimer’s dementia… Read More

#News #Regulatory

Brain Awareness Week
#Brain #Brain Awareness Week #Brain disease #Dementia #Drug discovery #Parkinson's #Stroke

Brain Awareness Week: the wonders of brain science

DDW’s Diana Spencer reviews some of the advances in drug discovery for diseases of the brain in the last month. Brain Awareness Week is an annual global campaign that takes place from March 13-19, aimed at raising awareness and support for brain science and issues related to the brain and… Read More

#Exclusive Content

Tau proteins
#Alzheimer's #Cognitive impairment #Dementia #Tau protein

Study reveals new therapeutic target in neurodegenerative disease

Early-cognitive decline may result from a shift in the ratio of a protein sub-type in our brain cells triggering cell-loss, according to a new study. The discovery, published in Scientific Reports, provides a new therapeutic target to prevent the onset of neurodegenerative diseases including dementia and Alzheimer’s. It is the… Read More

#News

Dementia
#AAV #Cell and gene therapy #Cell and Gene Therapy Catapult #Dementia

New partnership looks to gene therapy for dementia  

The Cell and Gene Therapy Catapult (CGT Catapult) has partnered with the UK Dementia Research Institute (UK DRI) to help advance the development of adeno-associated virus (AAV) based gene therapies for dementia.  Through the collaboration, the CGT Catapult will work with UK academic centres and the UK… Read More

#News

#Biologics / Biotechnology #Biotechnology #Biotherapeutics #Dementia

Dementia Discovery Fund enhances its neuroscience R&D expertise

The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, has announced the appointments of Dr Lynne Hughes and Dr James Summers as Venture Partners, bringing additional expertise in neuroscience research and development. Dr Jonathan Behr, Partner at The… Read More

#News